NASDAQ: ACLXArcellx Inc Stock
$56.22-1.67 (-2.88%)
Updated Dec 8, 2023
ACLX Price
$56.22
Fair Value Price
$62.10
Market Cap
$2.74B
52 Week Low
$25.59
52 Week High
$59.09
P/E
-21.22x
P/B
10.29x
P/S
36.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$47.17M
Earnings
-$129.53M
Gross Margin
100%
Operating Margin
-264.78%
Profit Margin
-274.6%
Debt to Equity
1.31
Operating Cash Flow
$122M
Beta
0.81
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACLX Overview
Arcellx, Inc., a clinical-stage biotechnology company developing immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, ACLX-001, ACLX-002, ACLX-003; and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in 2016/01. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, MD.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACLX ($56.22) is undervalued by 9.47% relative to our estimate of its Fair Value price of $62.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACLX ($56.22) is not significantly undervalued (9.47%) relative to our estimate of its Fair Value price of $62.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACLX due diligence checks available for Premium users.
Be the first to know about important ACLX news, forecast changes, insider trades & much more!
ACLX News
Valuation
ACLX fair value
Fair Value of ACLX stock based on Discounted Cash Flow (DCF)
Price
$56.22
Fair Value
$62.10
Undervalued by
9.47%
ACLX ($56.22) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACLX ($56.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.22x
Industry
11.7x
Market
31.32x
ACLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.29x
Industry
5.42x
ACLX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACLX's financial health
Profit margin
Revenue
$15.0M
Net Income
-$39.3M
Profit Margin
-263%
ACLX's Earnings (EBIT) of -$124.90M... subscribe to Premium to read more.
Interest Coverage Financials
ACLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$614.2M
Liabilities
$348.1M
Debt to equity
1.31
ACLX's short-term assets ($491.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACLX's short-term assets ($491.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.1M
Investing
-$160.0M
Financing
-$5.0M
ACLX's operating cash flow ($121.81M)... subscribe to Premium to read more.
Debt Coverage Financials
ACLX vs Biotech Stocks
Arcellx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.